ArticleBMC surgery2026
Efficacy of intraoperative topical Sapylin (OK-432) for preventing lymph leakage following inguinal lymph node dissection in melanoma: a retrospective cohort study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether intraoperative topical Sapylin (OK-432) reduces postoperative lymphatic leakage after inguinal lymph node dissection (ILND) in melanoma patients.
methodsThis retrospective study included 105 melanoma patients who underwent unilateral ILND (2022-2025). The study group (n = 51) received intraoperative topical Sapylin; the control group (n = 54) received saline. Both groups underwent Sartorius muscle flap coverage. Lymphatic leakage incidence, recovery indicators, and complications were compared. Logistic regression was used to identify risk factors.
resultsLymphatic leakage was significantly lower in the Sapylin group (9.8% vs. 25.9%, P = 0.03). Multivariable analysis confirmed age ≥ 60 years as an independent risk factor (OR = 4.93, P = 0.01) and Sapylin use as an independent protective factor (OR = 0.30, P = 0.04). The study group also showed reduced total drainage volume, shorter drain removal time, faster wound healing, and shorter hospital stay (all P < 0.05). No significant between-group differences were observed in fever or surgical site infection.
conclusionIntraoperative topical Sapylin is safe and effective for reducing postoperative lymphatic leakage and accelerating recovery after inguinal lymph node dissection for melanoma.
trial registrationThis trial was registered in the Chinese Clinical Trial Registry (ChiCTR) on September 23, 2025 (Registration Number: ChiCTR2500109640; URL: https://www.chictr.org.cn/showproj.html?proj=287559 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.